Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Madrigal Pharmaceuticals, Inc. filings document the company’s biopharmaceutical business, commercial reporting for Rezdiffra (resmetirom), and governance matters tied to its Nasdaq-listed common stock. Current reports include quarterly results furnished under Item 2.02, updates on Rezdiffra net sales and cash resources, and Regulation FD disclosures related to pipeline and licensing activity in MASH.
Other filings cover material agreements affecting Rezdiffra intellectual property and royalties, including amendments to a research, development and commercialization agreement, as well as proxy disclosures for director classes, board matters, executive compensation and equity incentive plans. The filing record also documents stockholder meeting proposals and corporate-governance actions for a commercial-stage biopharmaceutical company developing metabolic liver-disease therapies.
Madrigal Pharmaceuticals director Rebecca Taub reported new equity awards. She received 454 restricted stock units that vest on the earlier of June 17, 2027 or the company’s 2027 annual meeting, if she remains in service. She was also granted a stock option for 766 shares of common stock at an exercise price of $499.86 per share, expiring on June 17, 2036, with the same vesting schedule. Following these awards, she holds 452,667 shares of common stock directly and 655,540 shares indirectly through SQN LLC, where she and her spouse are managing members and she disclaims beneficial ownership except for any pecuniary interest.
Madrigal Pharmaceuticals director Richard S. Levy received new equity awards. He was granted 454 shares of common stock as restricted stock units and 766 stock options with an exercise price of $499.86 per share. Both awards vest in full on the earlier of June 17, 2027 or the company’s 2027 annual stockholder meeting, if he continues in service. After the grants, he directly owns 22,469 common shares.
Madrigal Pharmaceuticals director Jacqualyn A. Fouse reported receiving new equity awards. She was granted 454 shares of common stock in the form of restricted stock units at no cost, increasing her direct common stock holdings to 1,551 shares.
She was also granted stock options covering 766 shares of common stock at an exercise price of $499.86 per share, expiring on June 17, 2036. Both the restricted stock units and the options vest 100% on the earlier of June 17, 2027 or the company’s 2027 annual meeting of stockholders, provided she continues in service with Madrigal through that date.
Madrigal Pharmaceuticals director James M. Daly reported awards of company equity as part of his compensation. He received 454 restricted stock units, which represent an equivalent number of common shares when they vest. He was also granted a stock option for 766 shares of common stock at an exercise price of $499.86 per share.
Both the restricted stock units and the option vest 100% on the earlier of June 17, 2027 or the date of Madrigal’s 2027 annual meeting of stockholders, as long as he continues in service with the company. Following the grant, Daly directly holds 3,081 shares of common stock and the newly granted option on 766 shares.
Madrigal Pharmaceuticals director Daniel J. Brennan reported equity compensation awards. He received 404 shares of Common Stock as restricted stock units and a stock option for 681 shares at an exercise price of $499.86 per share. Both awards vest in full on the earlier of June 17, 2027 or the company’s 2027 annual stockholder meeting, if he remains in service. After these grants, Brennan directly holds 1,371 Common shares and 681 option shares.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
Madrigal Pharmaceuticals reported equity compensation awards related to board service by representatives of Baker Bros.-affiliated funds. On June 17, 2026, a total of 908 restricted stock units (RSUs) and 1,532 non-qualified stock options tied to Madrigal common stock were granted in the aggregate to Julian C. Baker and Dr. Raymond Cheong, who serve on the board as representatives of 667, L.P. and Baker Brothers Life Sciences, L.P. The stock options have a strike price of $499.86, fully vest on the earlier of June 17, 2027 or the 2027 annual stockholder meeting, and expire 10 years from grant. The filing explains that the Baker funds have an indirect proportionate pecuniary interest in these securities, the investment adviser has voting and dispositive power, and various Baker entities disclaim beneficial ownership except to the extent of their pecuniary interest. No open-market purchases or sales are reported; all transactions are classified as grants or awards.
Madrigal Pharmaceuticals used its latest annual meeting to update several compensation programs. On June 17, 2026, stockholders approved a new 2026 Stock Plan and a 2026 Employee Stock Purchase Plan, both previously adopted by the board and described in the company’s proxy statement.
The board also adopted a Nonqualified Deferred Compensation Plan, effective August 1, 2026, allowing selected executives and directors to defer portions of salary, bonuses, fees, and equity awards into notional investments tied to designated mutual fund options. The company may make discretionary contributions but does not currently intend to do so.
Separately, Madrigal entered a consulting agreement under which Dr. Rebecca Taub will transition from employee to consultant on July 1, 2026, providing scientific and medical guidance on MASH programs for an annual fee of $100,000, while continuing to receive the standard compensation paid to other non-employee directors.
Madrigal Pharmaceuticals Chief Medical Officer David Soergel reported an open-market sale of 1,042 shares of the company’s Common Stock on June 1, 2026 at an average price of $495.74 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 2, 2026, indicating it was pre-arranged. Following this sale, Soergel directly holds 10,033 shares of Madrigal Pharmaceuticals common stock.
MDGL: A Form 144 notice reports an intended sale of 1,042 shares of Common Stock (listed as value $518,155.34) and discloses a prior sale of 844 shares on 05/18/2026 for $435,419.60. The filing names David Soergel as the selling party and lists the securities as Restricted Stock Units.
Madrigal Pharmaceuticals director Richard S. Levy sold 5,682 shares of common stock in a series of open-market transactions on May 22, 2026. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2026, at weighted average prices between about $506.42 and $520.28 per share. Following these transactions, he directly holds 27,657 shares of Madrigal common stock.